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Abstract
Background
We developed and tested the effectiveness of a tailored health information technology
driven intervention: “Talking Prescriptions” (Talking Rx) to improve medication adherence in
a resource challenged environment.
Methods
We conducted a parallel, randomized, controlled, assessor-blinded trial at the Aga Khan
University (AKU), Karachi, Pakistan. Adults with diagnosis of cerebrovascular accident
(CVA) or coronary artery disease (CAD) diagnosed least one month before enrollment, on
anti-platelets and statins, with access to a mobile phone were enrolled. The intervention
group received a) Daily Interactive Voice Response (IVR) call services regarding specific
statin and antiplatelet b) Daily tailored medication reminders for statin and antiplatelet and
c) Weekly lifestyle modification messages for a period of 3 months. We assessed Medica-
tion adherence to statin and antiplatelets by a validated version of the 8-item Morisky Medi-
cation Adherence scale 8 (MMAS-8) at 3 months by a blinded assessment officer. Analysis
was conducted by intention-to-treat principle (ITT).
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Results
Between April 2015 and December 2015, 197 participants (99 in intervention and 98 in the
usual care group) enrolled in the Talking Rx Study. The dropout rate was 9.6%. Baseline
group characteristics were similar. At baseline, the mean MMAS-8 was 6.68 (SD = 1.28) in
the intervention group and 6.77 (SD = 1.36) in usual care group. At end of follow-up, the
mean MMAS-8 increased to 7.41(0.78) in the intervention group compared with 7.38 (0.99)
in usual care group with mean difference of 0.03 (S.D 0.13) (95% C.I [-0.23, 0.29]), which
was not statistically significant. (P-Value = 0.40) CVA patients showed a relatively greater
magnitude of adherence via the MMAS-8 at the end of follow up where the mean MMAS-8
increased to 7.29 (S.D 0.82) in the intervention group as compared to 7.07(S.D 1.24) in
usual care group with mean difference of 0.22 (SD = 0.22) 95% C.I (-0.20, 0.65) with (P-
value = 0.15). Around 84% of those on intervention arm used the service, calling at least 3
times and listening to their prescriptions for an average of 8 minutes. No user was excluded
due to technologic reasons.
Conclusion
The use of a phone based medication adherence program was feasible in LMIC settings
with high volume clinics and low patient literacy. In this early study, with limited follow up, the
program did not achieve any statistically significant differences in adherence behavior as
self—reported by the MMAS-8 Scale.
Trial registration
Clinical Trials.gov NCT02354040.
Introduction
Cardiovascular diseases (CVDs) namely cerebrovascular accidents (CVA) and or coronary
artery disease (CAD) are leading causes of death globally. An estimated 17.5 million people
died from CVDs in 2012, representing 31% of global deaths. Of these deaths, an estimated 7.4
million were due to CAD and 6.7 million were due to CVA. Over three quarters of CVD
related deaths take place in low- and middle-income countries. [1]
Pakistan is the sixth most populous country in the world. It has a reported lifetime preva-
lence of stroke symptoms of 19% in the transitional urban population. [2, 3, 4] One in four of
middle-aged adults in Pakistan suffers from CAD. [5] Thus, like other emerging LMIC coun-
tries, it bears a disproportionately large burden of vascular disease. Life style modification,
medical risk identification and control via adherence to medications are established cost effec-
tive strategies for secondary prevention. [6] Medications alone can reduce the risk of stroke by
30% and of Myocardial Infarction (MI) by 15%. [7] However, adherence, even in developed
countries is around 50%. [8] In Pakistan, reported adherence to cardiac medicines ranges
from 27–77% and about 68% to stroke medicines in the first 2 years after event. [9,10]
There is considerable room for improvement to increase adherence in population at risk
both in Lower Middle Income Countries (LMIC) and in Higher Income Countries (HIC) set-
tings. However, interventions to improve compliance like drug dairies, pill counters, auto-
mated reminders and social support would not be feasible in a resource poor, literacy
The Talking Rx Study
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challenged LMIC setting. [11] Due to an out of pocket, self-referral system, patients fre-
quently take multiple opinions and prescriptions from different physicians at the same time.
[12,13] This leads to increased risk for drug-drug interactions and a decline in adherence
behavior.
m-Health based strategies have the potential to be an inexpensive and easily accessible tool
to increase compliance and bridge the communication gap between health care providers and
users. [14] Cellular phone technologies have been used in the past to increase medication
adherence in HIV [15], smoking cessation [16], diabetes [17], maternal and child health care.
[18] According to the Pakistan Telecommunication Authority, the total cellular density in
Pakistan is reported to be 77% and 92% of Pakistan has internet coverage. [19] Leveraging this
fact, we developed and pilot tested a patient individualized tailored health information tech-
nology-driven intervention in Pakistani patients with CAD and CVA receiving care in the out-
patient setting of a busy tertiary care hospital. We hypothesized that IT based education via
interactive Talking Prescriptions would lead to an increase in medication adherence due to the
improved health literacy provided by talking prescriptions compared to usual care.
Methods and material
Trial design
The Talking Rx trial was a parallel-design, assessor-blinded, randomized controlled single cen-
ter trial enrolling patients suffering from CAD or CVA. The Talking Rx study was conducted
from April until December 2015. Research team members evaluating the participants at the
end of follow-up period were blinded to the assignment. The participants were randomized
into two parallel groups in a 1:1 ratio via block technique with usual care group receiving the
standard of care as per institutional guidelines while the parallel intervention group also
received Talking Rx intervention based on: 1) Daily Interactive Voice Response (IVR) call ser-
vices providing information about specific statin and antiplatelet, 2) Daily tailored medication
reminders for patients to take their statin and antiplatelet medication and 3) Weekly Life Style
Modification Messages that engaged the patient and were also related to medication adher-
ence. We chose statins and antiplatelet medications as the focus of our intervention as these
medications have been shown to decrease the risk of recurrent cardiovascular events in
patients with CAD and CVA. Following is a brief outline of the methodology used in the
study. For further details, please refer to the published protocol. [20]
Study setting
The Talking Rx trial was conducted at the Aga Khan University Hospital (AKUH) in Karachi,
Pakistan. All the patients admitting with CAD or CVA events receive standard of care treat-
ment according to International and institutional guidelines. The Talking Rx trail procedures
were performed at Clinical Trial Unit (CTU) of AKUH, which included assessment of eligibil-
ity, baseline assessment, process of randomization and administration of intervention and fol-
low-up visit.
Study participants
Potential participants were identified through daily screening of cardiology and neurology
outpatient clinic lists. Patients with history of CVA or CAD attending neurology and cardiol-
ogy clinics at AKUH, who fulfilled the study eligibility criteria and could provide written
informed consent, were recruited as study participants based on the following criteria:
The Talking Rx Study
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Eligibility criteria
Inclusion criteria.
• Age older than 18 years both male and female gender
• History of CVA or CAD [(MI, unstable angina, or coronary intervention performed via per-
cutaneous coronary intervention or coronary artery bypass grafting (CABG)]. These were
confirmed using objective modalities at the time of the episode (i.e., neuroimaging, electro-
cardiogram (ECG), cardiac catheterization, relevant blood tests, physician examination and
clinical confirmation in medical records).
• More than 1 month since last episode of CVA or CAD.
• Use of anti-platelets and statins both.
• Modified Rankin Score of 3 or less. (for CVA patients)
• Possession of a mobile phone that the patient has access to at all times. In the case of patients
who did not own a mobile phone or were unable to use a mobile phone, they were enrolled
if they had a primary caregiver available at all times who owned a cell phone.
• Ability to receive and comprehend an SMS (Short Message Service) in English or Urdu. In
the case of patients who themselves were unable to receive or comprehend an SMS, they
needed to have a caregiver available at all time who could perform the above-mentioned
tasks.
Exclusion criteria.
• Planned travel within 2 months of recruitment in an area where phone internet coverage is
known to be underdeveloped or not present.
• History of malignancy (diagnosed in the last 5 years and/or receiving active treatment)
requiring medication adjustment.
• Planned procedure (during the study time period of 3 months) which necessitates rapid
medication changes like CEA (Carotid Endarterectomy), CABG, or percutaneous coronary
intervention).
Randomization
The Clinical Trial Unit staff, separate administrative entities from the research staff at AKUH
performed randomization. Centrally Randomized computer generated random allocation
sequence was used by the CTU. For allocation concealment, opaque white envelopes were
used to ensure that the next assignment was not predictable. Participants were assigned to the
two groups in a parallel fashion in a 1:1 ratio. Block randomization technique with a block size
of 10 was used to make the next assignment unpredictable to the research team who were not
aware of block sizes.
Intervention group
Participants in the intervention group received daily Interactive Voice Response (IVR) call ser-
vices, daily prescription tailored medication reminders and once weekly life style modification
messages. The IVR service was tailored to each patient prescription for anti-platelets or statin.
The Talking Rx Study
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(“Fig 1 Study Activity Flow Diagram”) The intervention focused on two sets of medications
(anti-platelets and statins) widely used in the treatment of patients with CVA and CAD. The
information on IVR was available on four sets of generic anti-platelet medication, which
included Aspirin, Clopidogrel, Cilostazol and Prasugrel. The four sets of generic statins
included Atorvastatin, Rosuvastatin, Simvastatin and Ezetimibe. After randomization, partici-
pants were registered in the Talking Rx software system. This software was linked to a central
program. Optical Mark Recognition Sheet (OMR sheet) was used to mark patient’s prescrip-
tion. The marked OMR sheet was then scanned into the Talking Rx software to directly enter
patients tailored prescription in the software. Once the software received the prescription, the
data was transferred to the central program of IVR and participants received a welcome test
message which showed successful activation of IVR services tailored to patient’s prescription.
The welcome message contained a number and by dialing that number, participants were able
to receive IVR services. Once the participants made a free call on the specific number, the call
was registered on the central system and they received a call back where the IVR was played.
First, a mandatory message was played explaining the important instructions pertaining to all
medicines followed by the recording of their specific medicines. The participants had the
choice to listen to full recording or select different options listed on the IVR Menu. They could
listen to their strength (dose) of medicine, its prescribed frequency, how and the best time to
take the medicine, drug-drug and drug-food interactions and side effects. (“Fig 2 Flow diagram
of Interactive Voice Response (IVR)”) The participants had a choice to listen to each subcate-
gory serially, or targeted information as desired, once or multiple times. This service was
available free-of-cost 24/7. This modality focused on educating the patient regarding basic
mediation related literacy. It also addressed the common myths that surround medications in
health literacy challenged areas e.g., the myth that one can feel chronic disease symptoms, and
therefore, can stop taking medications by themselves. The content of the IVR was systemati-
cally developed by a qualified pharmacist and clinical team, based on evidence-based guide-
lines and recommendations and input by patients who had survived CVA and CAD via
iterative qualitative assessments. The content was reviewed and expert validated by a team of
stroke neurologist and cardiologist to authenticate its relevance and clarity.
In addition, participants also received a daily-automated SMS highly personalized to their
anti-platelet and statin prescription to remind them to take their medication. This SMS was
sent 5 days a week in the early afternoon, which was identified as the most convenient time by
the participants to receive reminder messages. Furthermore, one life style modification SMS
was sent only once weekly to reinforce the importance of medication adherence, lifestyle mod-
ifications and cardiovascular risk factors. (“Fig 3 Experience of Users in the Intervention
Group, Fig 4 Screen shots of IVR and SMS Reminders messages”) The intervention was aimed
to boost medication adherence and medication health literacy. The reminder SMS were
phrased using the behavior change intervention taxonomy devised by Michie et al. [21] The
specific content of the SMS was derived from the Social Cognitive Theory and Health Belief
Model of behavior change in health care. [22]
The Talking Rx program
The Talking Rx program was an IVR technology based program specifically designed by the
Aga Khan Development Network eHealth Resource Centre (AKDN eHRC) in collaboration
with the clinical team that worked in these high volume clinics. The application was custom-
ized for the program. It was not an open source system. The hardware and software details for
the program are as follows:
Hardware. The hardware used in the intervention is as follows:
The Talking Rx Study
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Fig 1. Study activity flow diagram.
https://doi.org/10.1371/journal.pone.0197671.g001
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• Laptop—A laptop was used to install the Talking Rx application, which was developed in-
house. Multiple users were able to login the application but one at a time. This laptop also
acted as a local server.
• Scanner—A scanner was connected with the laptop for scanning the Optical Mark Recogni-
tion (OMR) sheet where optical mark recognition is the process of capturing human-marked
data from a document.
Software. In order to develop the customized application we used the following software:
• PHP (server-side scripting language)–It is a server scripting language, and a powerful tool
for making dynamic and interactive web pages.
Fig 2. Flow diagram of Interactive Voice Response (IVR).
https://doi.org/10.1371/journal.pone.0197671.g002
The Talking Rx Study
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• SQL (Structured Query Language)–It is a domain-specific language used in programming
and designed for managing data held in a relational database management system, or for
stream processing in a relational data stream management system.
• Java—It is a general-purpose computer programming language that is concurrent, class-
based, object-oriented, and specifically designed to have as few implementation dependen-
cies as possible.
• MATLAB (Matrix Laboratory)–It is a multi-paradigm numerical computing environment.
MATLAB allows matrix manipulations, plotting of functions and data, implementation of
algorithms, and creation of user interfaces.
• XML (eXtensible Markup Language)–It is designed to store and transport data that is both
human- and machine-readable.
Fig 3. Experience of users in the intervention group.
https://doi.org/10.1371/journal.pone.0197671.g003
The Talking Rx Study
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Desktop-based imaging application. It was used for scanning the prescription page,
detecting markers of medications, dose and frequency and translating into an XML form
which was understandable by the web-based medical record application.
Web-based medical record application. This was a web-based application that was
locally hosted, which registered the patient, saved patient’s pharmacy data, translated XML
into record form and communicated with other messaging server through CSV files and
HTTP protocols.
This application sent CSV file to voice server using internet services. In addition to the
above mentioned applications, the system had a messaging and voice server. This server was
hosted at the service provider and contained an application which stored all audio files in
coded form (encrypted). The application accepts CSV file format from the web-based server
and binds specific audio files and messages based on the prescribed medicines with patient’s
mobile phone number. This server allows web-based medical record to send SMS to patients
through HTTP protocols and patients can call the server from their mobile phones to hear
their prescription “talk”.
Audio files:
The audio files were developed in house by a team of pharmacists, physicians and content
experts who reviewed the script, and they were recorded and reviewed with the support of the
Fig 4. Screen shots of IVR and SMS reminders messages.
https://doi.org/10.1371/journal.pone.0197671.g004
The Talking Rx Study
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i n—house Audio Visual Department and the eHealth resource centre where the studio was
provided. Prior to deployment, the content was played back and checked for inaccuracies and
finalized and edited recordings were added to the program.
There were two types of audio recordings:
General: This contains general messages recordings such as welcome message and thank you
message at the beginning and at the end of each call respectively; the doses of the medicines
such as 5mg, 10mg, 20mg etc.; the frequency of the medicines such as morning, evening,
night, before meal, after meal etc.
Specific: This contains medicine specific messages such as benefits, side-effects, contraindica-
tions, method of use of each medicine.
The third party application managed the audio recordings and played the recordings as per
the prescribed medicines to the patient. So when a patient calls, they hear only their prescribed
medicine details.
Technical flow. The technical flow of the intervention is as follows (Please refer to “Fig 5
Technical Details of Intervention Flow for further clarity”). Firstly, Patient Registration: The
patients were enrolled in the application by entering their demographic information such as
name, age, gender etc. The next step was, Acquistion and Processing: The medicines were pre-
scribed on an OMR sheet by shading in the area of the relevant medicine for the patient. These
OMR sheets were scanned by the scanner and shaded areas were detected by the image pro-
cessing algorithm developed using the MATLAB. This algorithm was then translated into Java
readable file i.e. JAR file. This JAR file passes the image through image processing algorithm
and provides values in XML. The detected values of the image processed, provides medication
name and other information that can be extracted from XML script using PHP coding. PHP
program can use Java script to use JAR file in web environment and extracted data from the
image can be stored in SQL database. The XML file is used to communicate with other messag-
ing server through Comma-separated Values (CSV) files and Hypertext Transfer Protocol
(HTTP). The OMR sheet, MATLAB, XML and PHP/Javascript are only necessary to get the
patient and prescription information into an SQL database so that the Talking Rx program
can then be activated in an electronic medical record system, this step may be skipped in
favour of a digital system and were necessary due to local context rather than the principle of
the system.
The CSV file was sent from the application to the third party server for the SMS and Inter-
active Voice Response (IVR) services. This server was hosted at the service provider and con-
tained an application which stored all encrypted audio files. The CSV file containing patient
information regarding demographics and medicines binds with the prescribed medicine-
based audio recordings and messages. The purpose of the messaging and server was to send
SMS, related to patient education and behaviour change, to patients through HTTP along with
IVR number. The system had a Voice Response capacity, the patients called the server from
their mobile phones using the provided IVR number to hear their prescription “talk”. The call
provides a welcome message and information on the prescribed medicines such as dose,
frequency, method of use, side effects, herbal-drug interaction etc. Based on diseases and pre-
scribed drugs, the web-based system sends customized messages to patients through messag-
ing sever periodically. Through this feature, behaviour change communication is established
to promote positive health related behaviour in patients. The data was monitored on the web
portal. The data is exportable and reviewable, providing user interface interaction data. (“Fig
6a and 6b Screen shot Web Portal”)
The Talking Rx Study
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Fig 5. Technical details of intervention flow for further clarity.
https://doi.org/10.1371/journal.pone.0197671.g005
The Talking Rx Study
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Usual care group
In the usual care group, participants received the usual standard of care provided for CVA and
CAD patients. This primarily consists of regular follow-up visits (frequency as per patient
needs) with their stroke neurologist or cardiologist.
Study helpline
In addition, every participant whether in the intervention or the usual care group also received
access to a helpline number where they could contact the research team during the study dura-
tion. Participants could post any queries pertaining to their illness or questions related to their
Fig 6. 6a and 6b. Screen shot web portal.
https://doi.org/10.1371/journal.pone.0197671.g006
The Talking Rx Study
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medications on this helpline number. These queries were answered within 24 hours by a study
physician.
Study procedures
Participants who fulfilled the eligibility criteria and provided written informed consent were
invited to the Clinical Trials Unit. All participants were assessed at baseline for data on socio-
demographic information, medical and prescription details. The baseline adherence score for
each participant was evaluated by the Urdu version of the 8-item Morisky Medication Adher-
ence Scale 8(MMAS-8- Urdu Version) [23, 24] followed by randomization to either the inter-
vention group or the usual care group. After allocation, the research staff explained the details
of the intervention to the participants. The participants were registered on the Talking Rx pro-
gram. The study team also demonstrated how to use the system by sending one test SMS on
participant’s mobile phone. In case of allocation to usual care group, the participants were
informed about their dates of follow-up at the end of 3 months. The study research staff
(medical doctors and pharmacist) was divided into two groups. Those who randomized and
administered the intervention were separate from those who performed assessment of study
outcomes. Those performing outcome assessment were geographically separate from the ran-
domization and intervention deployment team.
Follow-up and outcome ascertainment
Follow ups were performed at 3 months post intervention vs. usual care. In order to minimize
the dropout rate, participants in both groups were reminded one week prior to their planned
follow-up visit. Two day prior to visit, they were reminded through a SMS. If the participants
were not able to come for their follow-up at 3 months, a period of +14 days was permitted to
maximize follow-up. Participants, who were not able to come to CTU for follow-up because
they were not in the city, were contacted and their follow-up was performed on the telephone.
Outcome assessment was performed by trained study research staff who were blinded to the
assignments of participants.
Primary outcome measure
The outcome of interest was a change in medication adherence after 3 months of receiving the
Talking Rx intervention. Medication adherence was assessed at baseline and after 3 months in
both groups by administrating the Urdu version of the 8-item Morisky Medication Adherence
Scale 8 (MMAS-8 Urdu). [23, 24] The scale has been translated and validated in Urdu and has
a sensitivity of 46% and specificity of 60%. [24] The scale consists of eight questions. The maxi-
mum score is 8, score of< 6 denotes low adherence, 6 to<8 denotes medium adherence and a
score of 8 denotes high adherence. This study has used the Urdu validated scale of MMAS-8.
Process measures: Technical monitoring, recording deployment fidelity
and uptake
Continuous monitoring of data was performed by the technology team at AKDN eHRC to
assess the fidelity to the intended intervention during deployment by the operators and uptake
of the intervention by the users. We were able to record how many participants accessed and
used the intervention and what parts of the talking prescription were used repeatedly. The
digital server was also recording fidelity of deployment in that the data was flowing without
hitches as intended, monitoring access and interoperability issues due to separate phones and
The Talking Rx Study
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systems accessing the program. Data was collected on technology indicators like the total num-
bers of calls made on IVR and the average duration of IVR recordings.
Sample size calculation
The sample size was calculated to detect a difference of 1 point difference (SD = 2) on the pri-
mary outcome measure (MMAS-8) between the two groups. Based on these assumptions, the
estimated sample size requirement for the study was 86 participants in each group required to
achieve a power of 90% and significance level of 5% when testing a two-tailed hypothesis of
inequality of means. Accounting for a 15% attrition rate, the required sample size required for
the study was 100 participants in each group, making total of 200 participants to be random-
ized. The MMAS-8 categorizes low adherence as a score of<6 medium adherence as a score of
6 to<8, and high adherence as a score of 8. [24] Any 1-point shift is a clinically important
increase in medication adherence. Locally carried out studies have shown the effect of IT-
based interventions on this score in these ranges. [17, 25]
Statistical analysis
The analysis was performed based on the intention-to-treat principle. Analysis was performed
after the completion of follow-up for all study participants. For descriptive analysis, mean
with standard deviation or median with Interquartile Range (IQR) are reported based on nor-
mality assumptions for continuous data. For categorical data, frequency with percentages are
reported. The primary outcome analysis compared the improvement in medication adherence
level, assessed by the change in MMAS-8 score at 3 months of follow-up between the two
groups. For these analyses, MMAS-8 score was used as continuous variable. Independent t test
for two samples was applied to report the difference between the mean MMAS-8 scores for the
intervention and the usual care group. Further sub-group analyses were performed to study
the effect of intervention on CVA and CAD participants. Finally, we performed User interface
experience analysis to report the feasibility and the uptake of the intervention by the study par-
ticipants. [26] All analysis was performed on Stata version13.
Acceptability of intervention by participants
At the end of follow-up visit, participants were asked to share their opinions, experience and
recommendation on how to further improve the intervention. At exit follow-up interview,
we asked open-ended questions for end user feedback. All of the participants were asked to
respond to questions like what was your experience while using the intervention? What further
changes can be brought to the intervention? and share any practical experiences and opinions
regarding the intervention? In the end the feedback received, was analyzed by manual content
analysis to identify the relevant thematic findings obtained thorough qualitative based open-
ended questions.
Ethical review and patients confidentiality
The study protocol was approved by the Aga Khan University Ethical Review Committee
(ERC) with reference no 3165-MED-ERC_14. The study was also registered online at the
clinical trails.gov website with ClinicalTrials.gov Identifier NCT02354040. Research team
was trained and certified in Ethics and Good Clinical Practice (GCP) certification. The
team received one-week training before the start of the study. This training included study
design, patient confidentiality and ethical issues. Strict confidentiality and privacy was
ensured.
The Talking Rx Study
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All participants provided written informed consent at the time of recruitment which was
available in both English and Urdu. Participants had the right to withdraw from the study at
any time. If the stroke patient was not able to sign the informed consent due to their disability,
then consent was taken from their caregiver in the presence of a witness. Participants were
financially reimbursed for all costs pertaining to their follow-up visits. In addition, special care
was taken to maintain patient comfort level. Health promotional texts were only sent once
weekly at convenient times. In days of high security alerts and announced SMS blackouts, the
SMS was sent in advance in night to the participant to avoid participant anxiety or uncertainty
about continuity of care or reception of services. The data was saved in locked cabinets in the
PI office and key was accessible only to limited research staff. Special steps were taken to secure
the data on server. The data was completely encrypted thus maintaining patient confidential-
ity. The information was secured as it was locally hosted. The system was password protected
to prevent unauthorized access.
Pre-testing phase
The first phase of pre-testing of the application (alpha version) was performed by the AKDN
eHRC team. All technical glitches within the software were removed. In the second phase
(Beta version), the application was tested by the research team. The research team was regis-
tered on the software system. Bugs were identified and rectified. This improved version
(gamma version) of the application was pretested on actual patients (10% of the total sample
size) and the feedback was incorporated. The research team was given two-day training at
AKDN eHRC on how to operate the technology and administer the Talking Rx software appli-
cation to the participants. Beside this, AKDN eHRC team was also present on the field to iden-
tify any glitches. During this run-in period, participant received the Talking Rx Application,
glitches were identified and improvements were made. The glitches identified included issues
with IVR recordings, scanning of OMR sheet and connection of the software to IVR, Short
code issues, and network issues. This final version of the application was deployed during the
trial. During the trial, intervention did not undergo any changes in content and deployment
frequency.
Results
The Talking Rx study was conducted from April until December 2015. (“Fig 7 Flow Diagram
of the Study Participants”) We assessed 641 patients for eligibility, out of which 441 partici-
pants were excluded (163 did not match the eligibility criteria and 277 refused to participate in
the study). In total 197 participants were randomized into two groups. At the end study, 19
(9.6%) were lost to follow-up.
Baseline characteristics
A total of 197 participants were analyzed in the study, 99 in intervention group and 98 in the
usual care group. The mean age of participants in the intervention and the usual care group
was 59.1±11.6 and 57.7±11.1, respectively. Baseline characteristics were equally distributed
between the two groups. Table 1
Mean medication adherence
The baseline mean Morisky medication adherence score (MMAS-8) was slightly higher in
usual care group 6.77 (SD = 1.36) as compared to 6.68 (SD = 1.28) in the intervention group,
though the difference was not statistically significant at baseline. After 3 months of follow-up,
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Fig 7. Flow diagram of the study participants.
https://doi.org/10.1371/journal.pone.0197671.g007
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Table 1. Baseline characteristics of study participants.
Characteristics Intervention Group
(n = 99)
Frequency (%)
Usual Care Group
(n = 98)
Frequency (%)
Age in years# [Range] 59.1±11.6 [29–82] 57.7±11.1 [32–84]
Males 77(77%) 75(76.53%)
Years of education
Up to 10 years 37(37.37%) 35(35.71%)
Up to 16 years 50(50.50%) 53(54.08%)
Greater than 16 years 12(12.12%) 10(10.20%)
Family Status
Joint Family 50(50.50%) 41(41.83%)
Nuclear Family� 49(49.49%) 57(58.16%)
Monthly Family income in rupees (Conversion in US $)
Less than 10,000(<$95) 5(5.05%) 3(3.06%)
10,000–25,000($95-$238) 15(15.15%) 14(14.28%)
26,000–50,000($250-$476) 29(29.29%) 27(27.55%)
51,000–100000($486-$953) 27(27.27%) 31(31.63%)
> than 100000(>$953) 23(23.23%) 23(23.46%)
Duration of disease (in months) † 31(6–84) 24 (6–74)
Disease
CVA 50(50.50%) 47(47.95%)
CAD 49(49.49%) 51(52.04%)
NIHSS Score† (National Institute of Health Stroke Severity Scale) 1(0–2) 1(0–4)
Hypertension 63(63.63%) 63(64.28%)
Diabetes mellitus 50(50.50%) 55(56.12%)
Dyslipidemia 97(97.97%) 91(92.85%)
Atrial Fibrillation 1(1.01%) 2(2.04)
Carotid Stenosis 2(2.02%) 3(3.06%)
Coronary Stents placement 34(34.34%) 27(27.55%)
CABG 17(17.17%) 17(17.34%)
Valve Replacement 3(3.03%) 3(3.06%)
Central Obesity��
Male 66(66.66%) 64(65.30%)
Female 20(20.20%) 21(21.42%)
No obesity 13(13.13%) 13(13.26%)
Cigarette use
Smokers 4(4.04%) 10(10.20%)
Non-Smokers 95(95.95%) 88(89.79%)
History of tobacco chewing 14(14.14%) 8(8.16%)
Baseline Mean Morisky Medication adherence# 6.62± 1.29 6.75± 1.38
# Mean± S.D
† Median (IQR)
$ US dollars
�Nuclear family: means living with spouse and children only
�� Abdominal obesity, also known as central obesity, is the excessive abdominal fat around the stomach and
abdomen has built up to the extent that it is likely to have a negative impact on health. There is a strong correlation
between central obesity and cardiovascular disease. It is calculated by measuring individual waist circumference. The
cut-offs for waist circumference to report abdominal obesity is different for Asian population and different for both
the gender.
https://doi.org/10.1371/journal.pone.0197671.t001
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the MMAS-8 increased in both groups. While the increase in usual care group was less as com-
pared to intervention group (+0.61 SD = 1.62), there was larger increase in medication adher-
ence score of the intervention group (+0.73 SD = 1.31). The mean difference (95% C.I)
between the two group at follow-up was 0.03(S.D 0.13) (95% C.I [-0.23, 0.29]), which was not
statistically significant. (p-Value = 0.40) Table 2.
Sub-group analysis
We performed a subgroup analysis on CVA and CAD patients. For CVA patients, the baseline
mean MMAS-8 was almost similar in both groups in usual care group 6.67(S.D 1.37) as com-
pared to 6.63 (S.D 1.33) in intervention group, the difference was not statistically significant at
the baseline. After 3 months of follow-up, the MMAS-8 increased in both groups. While the
increase in usual care group was less (+0.4 SD = 1.38), there was larger increase seen in medi-
cation adherence score in the intervention group as compared to usual care group (+0.66
SD = 1.32) from baseline. The mean difference (95% C.I) was of 0.22 (SD = 0.22) 95% C.I
(-0.20, 0.65) with (P-value = 0.15) at the end of follow-up between the two groups was not sta-
tistically significant. Table 2. For CAD patients, baseline mean MMAS-8 score was higher in
the usual care group 6.86 (S.D 1.38) as compared to 6.58(S.D 1.27) in intervention group,
although the difference was not statistically significant at baseline. After 3 months of follow-
up, the increase in MMAS-8 was slightly higher in the intervention group (+0.98 SD = 1.26) as
compared to usual care group (+0.77 SD = 1.38) from baseline. The mean difference (95% C.I)
was of -0.06 (SD = 0.13) (95% C.I = -0.39, 0.19) (p-value = 0.69) at the end of follow-up
between the two groups which was not statistically significant tested through Independent t
test for two samples.
Acceptability and sustainability of intervention: End-User feedback via
open ended interviews
Open ended interviews of all participants in the intervention was performed at the time of exit
interview of the study. All participants were asked three qualitative questions: How did you
find the experience of the intervention? What further changes can be made to the interven-
tion? Share your experiences and opinions regarding the intervention? The responses were
recorded and summary themes were identified and presented here.
Evaluation of program by participants via open ended interviews. All of the partici-
pants reported being satisfied with the intervention. They found it an excellent, convenient,
Table 2. MMAS-8 scores at baseline and 3 months of follow-up among patients randomized to the intervention and usual care groups and MMAS-8 scores at base-
line and follow-up among patients with CVA & CAD randomized to the intervention and usual care groups.
Intervention group (n = 99) Usual care group (n = 98) Mean difference� (95% C.I) P-value
Baseline 3 Months Baseline 3 Months
All Participants 6.68(1.28) 7.41(0.78) 6.77(1.36) 7.38 (0.99) 0.03 (0.13) (-0.23, 0.29) 0.4
Intervention group (n = 50) Usual care group (n = 47) Mean difference� (95% C.I) P-value
Baseline 3 Months Baseline 3 Months
CVA participants only 6.63(1.33) 7.29 (0.82) 6.67(1.37) 7.07(1.24) 0.22(0.22) (-0.21, 0.66) 0.15
Intervention group (n = 49) Usual care group (n = 51) Mean difference� (95% C.I) P-value
Baseline 3 Months Baseline 3 Months
CAD Participants only 6.58(1.27) 7.56(0.71) 6.86(1.38) 7.63(0.59) -0.06(0.13) (-0.39, 0.19) 0.69
�Mean (S.D)
P-value calculated by Independent t test for two samples
https://doi.org/10.1371/journal.pone.0197671.t002
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useful and informative way of getting knowledge regarding their prescription medicines.
Majority felt that the intervention increased their awareness regarding medication usage and
side effects. Participants wanted Talking Rx to continue for longer than the trial stipulated
duration. They also expressed a desire to receive information in a similar format for other
medications as well. Participants stated that the SMS reminders helped them remain adherent
with their medicines. Most participants found life style modification messages to be beneficial.
End-user recommendations and changes suggested. The future recommendation and
suggestion included the IVR information to be available in written form as well like a of a text
message. Some recommended to reduce the total duration of IVR call and provide information
in a more simplified way. Majority of the participants wanted to include information regarding
local resources where medicines are easily available. Participants especially stroke patients
wanted to receive reminders messages for every dose of their medication. Others suggestions
were to include expansion of the intervention beyond two languages (English and Urdu) used
in the current study and to add pictorial messages to further improve the understanding of
what medications do for those who would learn better through images and videos etc.
Uptake of intervention by the participants. The uptake of Talking Rx was 84.8%. Table 3
The total number of IVR calls made by the participants in the intervention group was 286
calls. The average duration of IVR recording listened to by the participants was around 8 min-
utes. The most frequent option accessed by the participants was the correct strength of medi-
cines (27.4%) followed by the frequency of medicine (14.4%). Table 4
Table 3. User interface experience.
Frequency (%)
1 Total No of Participant called 84
2 Uptake of intervention 84(84.84%)
3 Total number of calls made on IVR 286
4 Average number of calls � 2.9± 4.10
5 Average Duration of phone calls in minutes� 8.72± 13.48
6 Average Duration of phone calls in minutes# 4.73[9.9]
�Mean± S.D
# Median [IQR]
https://doi.org/10.1371/journal.pone.0197671.t003
Table 4. Various IVR options listened to by the participants.
Frequency (%)
1 Complete information on medicine 36(7.77%)
2 What is dosage (strength) of your medicine 127(27.42%)
3 What is frequency for intake of your medicine 67(14.47%)
4 General information regarding dosage of medicine 53(11.44%)
5 How to properly use your medicine 14(3.02%)
6 How to correctly take your medicine 42(9.07%)
7 What is the purpose of using this medicine? 43(9.28%)
8 What are side effect of your medicine 18(3.88%)
9 What are food-drug interaction 37(7.99%)
10 What are drug-herbal medicine interaction 26(5.61%)
IVR = interactive voice response
https://doi.org/10.1371/journal.pone.0197671.t004
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Discussion
The Talking Rx trial is a clinical trial that reports the effectiveness and feasibility of an interac-
tive IT based program to improve medication adherence in stable CVA and CAD patients in a
resource challenged setting. The study demonstrated the feasibility of IT based interventions
in settings where mobile density and internet coverage is exceptionally excellent despite pov-
erty and other developmental challenges. Participant uptake of the intervention was greater
than 80%, there were no exclusions based on technical reasons or lack of mobile phone and
mobile coverage In this clinical trial, the intervention did not achieve a statistically significant
difference in adherence behavior as measured by the self-reported MMAS-8 scale.
There are several explanations for the observation of the effect on adherence, which
improved in the intervention, but failed to achieve statistical significance. Our results may
have been affected by a limited duration of follow up; a sustained intervention may have been
able to achieve more robust results in adherence behavior. Another explanation for the
observed effect is the nature of the population itself, these participants had suffered strokes
and heart attacks and received specialist tertiary care, this effected their baseline adherence
behavior as compared to populations not exposed to specialist centered care, thus, their base-
line adherence was much higher than we anticipated and therefore, the change in medication
adherence was low. Most of the participants already had good adherence at baseline as mea-
sured by MMAS-8 and therefore, potential for incremental benefit associated with the inter-
vention was small. In future study designs, we would choose participants that report poor
baseline adherence and follow them for longer periods of time- upto 6 months. We chose the
MMAS-8 as a suitable reporting measure for adherence as this scale has been used in a similar
setting previously and it has been translated and validated in Urdu which is the national lan-
guage of Pakistan. The MMAS-8 was assessed by a research officer in person on follow up visit
in person to minimize the effect of social desirability bias that would certainly occur if simple
mail in questionnaires were used. However, the social desirability bias is not entirely ruled out
in this study and may have biased the results towards minimal effect. It is possible that if more
objective measures for measuring intervention effect were chosen e.g. medication refill data or
biological measures e.g. low-density lipoprotein cholesterol levels, we may have seen an a
larger intervention effect. However, these measures were not logistically feasible in our setting,
given non-availability of electronic records with most patients filling their medications from
pharmacies in the open market without any standardized documentation, medication refill
data could not be obtained. Biochemical tests are costly and impractical in a resource con-
strained environment and would require repeat hospital visits (which participants cannot
afford both due to social and financial reasons) and which would also increase patient-pro-
vider interaction and impact the results of the intervention positively as a confounding co—
intervention. Electronic pillboxes may potentially provide results that are more accurate.
However, a vascular patient’s prescription which includes drugs for multiple risk factors and
this creates a challenge capturing actual compliance. Simply opening an electronic pill
box registers a dose as administered even if the patient takes only one medicine out of the
three that he is prescribed for that time. In future studies, we plan to evaluate the medication
adherence through telephonic unannounced pill counts methods, Skype calls or using objec-
tive intermediate outcome measures. Additionally, we observed that, the provision of study
helpline number to participants in both groups could have affected our study results. Although
this help line was not designed as a co-intervention, we believe that it did become a resource
for participants enrolled in the usual care group. There was a higher use of help line resources
in the control group and this may have resulted in a small-observed difference in medication
adherence associated with the intervention in the control group and subsequent decrease in
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inter-group difference. Lastly, a limitation of this study is that we did not study the effect of
intervention on improving patient health related outcomes like decrease in mortality and
recurrent strokes or cardiac outcomes that are targets for future larger scale clinical trials.
Although we did not achieve our primary outcome measure, we were able to demonstrate
the operational feasibility of using technology driven intervention in LMIC settings. No partic-
ipant was excluded due to technological reasons and greater than two thirds (84%) used the
intervention to learn about their medications. In open-ended interviews, most participants
wanted Talking Rx to continue for longer than the trial stipulated duration and found it to be a
useful adjunct to the physician visit.
Despite the limitations discussed above, efforts at enabling patients to adhere to medica-
tions, which are lifelong, and increasing their prescription knowledge is essential in LMIC set-
tings. In Pakistan, there are about 10 plus brand names for each generic medication which
becomes a huge source of prescription error as most medications are accessed over the
counter. [27] Drug-dispensing time in the public sector is insufficient for patient instruction,
with greater than 3 medications per patient. Despite these regional challenges, the potential to
leverage mobile technology to improve chronic disease outcomes is greatly untapped. Pakistan
has widespread mobile connectivity, with a cellular density of 77% and more than 137 million
mobile users who exchanged 301.7 billion SMS during 2014, a national electronic identifica-
tion database, low internet and text messaging costs, and availability of 3G and 4G mobile
internet. [19]These infrastructure enablers were exploited in TalkingRx.
The major strengths of our study include randomized study design with allocation conceal-
ment, blinded outcome assessment, and alignment with standardized guidelines for research
in m-health. [14, 28] The content of the intervention was designed by a team of experienced
health professionals from both LMIC and developed countries, using evidence based guide-
lines and grounded in Health Theory. [29, 30] The application was designed by biomedical
engineers and programmers working directly with physicians and patient feedback to keep the
application simple and user friendly for the community that was to test it. The intervention
can be easily replicated in other public hospitals due to the low cost of running it. The technol-
ogy has the potential for sustainability as it doesn’t require any large-scale capital investments
in existing hospital systems and does not require extra personnel or human resources.
Conclusion
In conclusion, an IVR/SMS based health IT driven was feasible in a busy hospital settings in a
resource-constrained setting, although, the intervention did not significantly improve medica-
tion adherence it was well received by end users.
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